The Company has completed its share buyback program. The Company has acquired a total of 33 041 own shares at a price per share of NOK 130.6672. A report of all the transactions relating to the buy-back programme, in a detailed form and in an aggregated form is attached.
The shares acquired is used for the Company's incentive scheme and sold to employees.
After the acquisition and sale to employees, Photocure owns 15,666 own shares in the Company.
For further information, please contact:
CFO Erik Dahl
Tel: +47 450 55 000
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This is information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052, and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.